Digital Therapeutics Market to be Worth $56.34 Billion by 2031
Meticulous Research®—a
leading global market research company, published a research report
titled ‘Digital Therapeutics Market Size, Share, Forecast, & Trends
Analysis by Application (Mental Health, Diabetes, Respiratory, Neurology,
Addiction, Rehabilitation, Oncology, Sleep Disorder) Type (Disease Prevention,
Management) End User—Global Forecast to 2031.’ According to this latest
publication, the digital therapeutics market is projected to reach $56.34
billion by 2031 at a CAGR of 31.5%.
This market is
experiencing growth driven by the rising prevalence of chronic diseases, a
growing focus on reducing healthcare costs, the increasing adoption of
preventative healthcare products, and the broader acceptance of digital
healthcare solutions. However, concerns over data privacy related to digital
therapeutics (DTx) applications are hindering the market's expansion.
In addition,
increasing investment by key players for product development and increasing
adoption of DTx in emerging economies are providing opportunities for market
growth. However, the low awareness of digital therapeutic products and the
lengthy and tedious regulatory approval process are major challenges impacting
market growth.
Key Players:
The key players
operating in the global digital therapeutics market are Noom, Inc. (U.S.),
2Morrow Inc. (U.S.), GAIA AG (Germany), ResMed Inc. (U.S.), Canary Health
(U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.),
Biofourmis Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), Limbix
Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Glooko, Inc. (U.S.),
and Virta Health Corp. (U.S.).
The digital
therapeutics market is segmented by Type, Application, and End User.
Among the types
studied in this report, in
2024, the disease management and treatment DTx segment is expected to account
for the largest share of 76.5% of the digital therapeutics
market. The large market share of this segment is driven by the availability of
cost-effective mHealth platforms, the growing need to control healthcare costs,
substantial investments in digital health, and strategic collaborations among
stakeholders to develop and launch digital therapeutic platforms for disease
treatment and management.
Among the
applications studied in this report, in 2024, the mental health segment is expected to account for the
largest share of the digital therapeutics market. The largest share of the
segment is attributed to the rising prevalence of mental health issues, such as
stress, anxiety, and depression. Additionally, the loss in productivity caused
by mental health challenges and the growing demand for cost-effective solutions
for managing stress and depression are key factors driving the segment's
substantial market share.
Among the
end users studied in this report, the individual consumers segment is slated to register the highest
CAGR during the forecast period. The rapid growth of this segment is driven by
the growing awareness and approval of digital therapeutic solutions, the
widespread adoption of mHealth platforms, and the increasing trend of
preventive healthcare among patients. Digital therapeutics software also
enables patients to reduce medication dosages by promoting healthier lifestyles
and tracking symptoms and health status. Furthermore, the use of digital
therapeutic platforms supports patients in self-managing their conditions
through continuous monitoring and early detection of disease signs,
facilitating preventative care.
Among the
geographies studied in this report, in 2024, North America is expected to account for the largest
share of 43.6% of the digital therapeutics market. The large
share of this market is driven by the growing adoption of digital health
products, the rising incidence of chronic diseases, and government initiatives
supporting digital healthcare. Additionally, favorable reimbursement policies
for digital therapeutics are improving accessibility and affordability of
disease management, helping to reduce overall healthcare costs. For example, in
the U.S., a group of policymakers reintroduced the "Access to Prescription
Digital Therapeutics Act of 2023" in the Assembly, which includes
provisions for covering prescription digital therapeutics under Medicaid and
Medicare.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5427
Key questions
answered in the report-
- Which are the high-growth market segments
in terms of type, application, end user, and regions/countries?
- What was the historical market for digital
therapeutics across the globe?
- What are the market forecasts and
estimates for the period 2024–2031?
- What are the major drivers, restraints,
challenges, opportunities, and trends in the global digital therapeutics
market?
- Who are the major players in the digital
therapeutics market?
- How is the competitive landscape, and who
are the market leaders in the global digital therapeutics market?
- What are the recent developments in the
digital therapeutics market?
- What do the major players adopt the
different strategies in the digital therapeutics market?
- What are the geographical trends and
high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment